AR131126A1 - Anticuerpos anti-cd137 y métodos de uso - Google Patents
Anticuerpos anti-cd137 y métodos de usoInfo
- Publication number
- AR131126A1 AR131126A1 ARP230103131A ARP230103131A AR131126A1 AR 131126 A1 AR131126 A1 AR 131126A1 AR P230103131 A ARP230103131 A AR P230103131A AR P230103131 A ARP230103131 A AR P230103131A AR 131126 A1 AR131126 A1 AR 131126A1
- Authority
- AR
- Argentina
- Prior art keywords
- antigen
- human
- seq
- antibody
- binding fragment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente divulgación proporciona anticuerpos o su fragmento de unión a antígeno que se unen específicamente a CD137 humano, anticuerpos multiespecíficos y fragmentos de unión a antígeno de los mismos que se unen específicamente a GPC3 humano y CD137, una composición farmacéutica que comprende dicho anticuerpo, y uso del anticuerpo, anticuerpo multiespecífico o de la composición, para el tratamiento de una enfermedad, tal como el cáncer. Reivindicación 1: Un anticuerpo o su fragmento de unión a antígeno que se une específicamente a CD137 humano, donde (1) el anticuerpo o su fragmento de unión a antígeno se une específicamente a un epítopo que comprende o consiste en los residuos de aminoácidos Phe36, Asp38, Pro49, Pro50, Asn51, Thr61, Cys62, Asp63, Ile64, Gln67 de CD137 humano (SEQ ID Nº 35); (2) el anticuerpo o su fragmento de unión a antígeno se une específicamente a un epítopo que comprende o consiste en los residuos de aminoácidos Ser55, Ala56, Arg75, Glu85, Ala97 y Gly98 de CD137 humano (SEQ ID Nº 35); o (3) el anticuerpo o su fragmento de unión a antígeno se une específicamente a un dímero de CD137 humano que comprende o consiste en un primer monómero de CD137 humano y un segundo monómero de CD137 humano, donde el anticuerpo o su fragmento de unión a antígeno se une específicamente a un epítopo del primer monómero de CD137 humano (SEQ ID Nº 35) que comprende o consiste en los residuos de aminoácidos Phe36, Asp38, Pro49, Pro50, Asn51, Thr61, Cys62, Asp63, Ile64, Gln67, y el anticuerpo o su fragmento de unión a antígeno se une específicamente a un epítopo del segundo monómero de CD137 humano (SEQ ID Nº 35) que comprende o consiste en los residuos de aminoácidos Ser55, Ala56, Arg75, Glu85, Ala97 y Gly98; y/o el anticuerpo o su fragmento de unión a antígeno se une a un dímero de CD137 humano y promueve el agrupamiento de CD137 humano. Reivindicación 2: Un anticuerpo o su fragmento de unión a antígeno que se une específicamente a CD137 humano, que comprende: (i) una región variable de cadena pesada (VH) que comprende (a) una HCDR1 (Región Determinante de Complementariedad de Cadena Pesada 1) de SEQ ID Nº 1, (b) una HCDR2 de SEQ ID Nº 2, y (c) una HCDR3 de SEQ ID Nº 3; o (ii) una región variable de cadena pesada que comprende (a) una HCDR1 de SEQ ID Nº 1, (b) una HCDR2 de SEQ ID Nº 10, y (c) una HCDR3 de SEQ ID Nº 3. Reivindicación 14: Un método de tratamiento del cáncer que comprende administrar a un paciente que lo necesita una cantidad terapéuticamente eficaz del anticuerpo o su fragmento de unión a antígeno de cualquiera de las reivindicaciones 1 - 12, o la composición farmacéutica de la reivindicación 13. Reivindicación 15: El método de la reivindicación 14, donde el cáncer es cáncer gástrico, cáncer de colon, cáncer pancreático, cáncer de mama, cáncer de cabeza y cuello, cáncer de riñón, cáncer de hígado, cáncer de pulmón, cáncer de pulmón de células pequeñas, cáncer de pulmón de células no pequeñas, cáncer de ovario, cáncer de piel, mesotelioma, linfoma, leucemia, mieloma y sarcoma. Reivindicación 19: Un anticuerpo multiespecífico o su fragmento de unión a antígeno que comprende por lo menos un primer dominio de unión a antígeno que se une específicamente a un antígeno asociado a tumor humano (TAA), y por lo menos un segundo dominio de unión a antígeno que se une específicamente a CD137 humano, donde el segundo dominio de unión a antígeno es (1) un anticuerpo o su fragmento de unión a antígeno que se une específicamente a un epítopo que comprende o consiste en los residuos de aminoácidos Phe36, Asp38, Pro49, Pro50, Asn51, Thr61, Cys62, Asp63, Ile64, Gln67 de CD137 humano (SEQ ID Nº 35); (2) un anticuerpo o su fragmento de unión a antígeno que se une específicamente a un epítopo que comprende o consiste en los residuos de aminoácidos Ser55, Ala56, Arg75, Glu85, Ala97 y Gly98 de CD137 humano (SEQ ID Nº 35); o (3) un anticuerpo o su fragmento de unión a antígeno que se une específicamente a un dímero de CD137 humano que comprende o consiste en un primer monómero de CD137 humano y un segundo monómero de CD137 humano, donde el anticuerpo o su fragmento de unión a antígeno se une específicamente a un epítopo del primer monómero de CD137 humano (SEQ ID Nº 35) que comprende o consiste en los residuos de aminoácidos Phe36, Asp38, Pro49, Pro50, Asn51, Thr61, Cys62, Asp63, Ile64, Gln67, y el anticuerpo o su fragmento de unión a antígeno se une específicamente a un epítopo del segundo monómero de CD137 humano (SEQ ID Nº 35) que comprende o consiste en los residuos de aminoácidos Ser55, Ala56, Arg75, Glu85, Ala97 y Gly98; y/o el anticuerpo o su fragmento de unión a antígeno se une a un dímero de CD137 humano y promueve el agrupamiento de CD137 humano. Reivindicación 20: Un anticuerpo multiespecífico o su fragmento de unión a antígeno, que comprende por lo menos un primer dominio de unión a antígeno que se une específicamente a un antígeno asociado a tumor humano (TAA), y por lo menos un segundo dominio de unión a antígeno que se une específicamente a CD137 humano, donde el segundo dominio de unión a antígeno comprende: (i) una región variable de cadena pesada (VH) que comprende (a) una HCDR1 de SEQ ID Nº 1, (b) una HCDR2 de SEQ ID Nº 2, y (c) una HCDR3 de SEQ ID Nº 3; o (ii) una región variable de cadena pesada (VH) que comprende (a) una HCDR1 de SEQ ID Nº 1, (b) una HCDR2 de SEQ ID Nº 10, y (c) una HCDR3 de SEQ ID Nº 3.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022133148 | 2022-11-21 | ||
| CN2022133147 | 2022-11-21 | ||
| CN2023126252 | 2023-10-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR131126A1 true AR131126A1 (es) | 2025-02-19 |
Family
ID=91195249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230103131A AR131126A1 (es) | 2022-11-21 | 2023-11-21 | Anticuerpos anti-cd137 y métodos de uso |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250154279A1 (es) |
| EP (1) | EP4623005A1 (es) |
| JP (1) | JP2025539145A (es) |
| KR (1) | KR20250110345A (es) |
| CN (5) | CN122255279A (es) |
| AR (1) | AR131126A1 (es) |
| AU (1) | AU2023384497A1 (es) |
| CL (1) | CL2025001474A1 (es) |
| CO (1) | CO2025006994A2 (es) |
| IL (1) | IL320949A (es) |
| MX (1) | MX2025005847A (es) |
| TW (1) | TW202421665A (es) |
| WO (1) | WO2024109678A1 (es) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10875926B2 (en) * | 2015-09-22 | 2020-12-29 | Dingfu Biotarget Co., Ltd. | Fully human antibody against human CD 137 |
| BR112019017628A2 (pt) * | 2017-02-24 | 2020-07-07 | Macrogenics, Inc. | molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição |
| EP3615574B1 (en) * | 2017-04-26 | 2026-06-24 | Eureka Therapeutics, Inc. | Constructs specifically recognizing glypican 3 and uses thereof |
| SG10201913147WA (en) * | 2017-07-11 | 2020-02-27 | Compass Therapeutics Llc | Agonist antibodies that bind human cd137 and uses thereof |
| CA3082297A1 (en) * | 2017-11-13 | 2019-05-16 | Crescendo Biologics Limited | Molecules that bind to cd137 and psma |
| CN110003332B (zh) * | 2018-01-05 | 2021-05-11 | 上海原能细胞医学技术有限公司 | Cd137抗体及其应用 |
| US12227582B2 (en) * | 2019-01-02 | 2025-02-18 | Qlsf Biotherapeutics Inc. | CD137 agonist antibodies and uses thereof |
| JP7476219B2 (ja) * | 2019-02-26 | 2024-04-30 | ピエリス ファーマシューティカルズ ゲーエムベーハー | Cd137およびgpc3に特異的な新規融合タンパク質 |
| KR20220145859A (ko) * | 2020-02-28 | 2022-10-31 | 상하이 헨리우스 바이오테크, 인크. | 항cd137 작제물, 다중 특이적 항체 및 그 용도 |
| CA3177098A1 (en) * | 2020-06-05 | 2021-12-09 | Pieris Pharmaceuticals Gmbh | Multimeric immunomodulator targeting 4-1bb |
| CN117916272A (zh) * | 2020-12-30 | 2024-04-19 | 上海药明生物技术有限公司 | 多特异性抗原结合蛋白 |
-
2023
- 2023-11-20 CN CN202610453333.2A patent/CN122255279A/zh active Pending
- 2023-11-20 KR KR1020257020688A patent/KR20250110345A/ko active Pending
- 2023-11-20 EP EP23893768.4A patent/EP4623005A1/en active Pending
- 2023-11-20 WO PCT/CN2023/132564 patent/WO2024109678A1/en not_active Ceased
- 2023-11-20 CN CN202610286130.9A patent/CN122011199A/zh active Pending
- 2023-11-20 AU AU2023384497A patent/AU2023384497A1/en active Pending
- 2023-11-20 CN CN202511287789.8A patent/CN121378482A/zh active Pending
- 2023-11-20 CN CN202610460411.1A patent/CN122277746A/zh active Pending
- 2023-11-20 IL IL320949A patent/IL320949A/en unknown
- 2023-11-20 JP JP2025529229A patent/JP2025539145A/ja active Pending
- 2023-11-20 CN CN202380079710.5A patent/CN120225562A/zh active Pending
- 2023-11-21 TW TW112145023A patent/TW202421665A/zh unknown
- 2023-11-21 AR ARP230103131A patent/AR131126A1/es unknown
-
2024
- 2024-11-20 US US18/954,427 patent/US20250154279A1/en active Pending
-
2025
- 2025-05-19 CL CL2025001474A patent/CL2025001474A1/es unknown
- 2025-05-19 MX MX2025005847A patent/MX2025005847A/es unknown
- 2025-05-27 CO CONC2025/0006994A patent/CO2025006994A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024109678A1 (en) | 2024-05-30 |
| CN122011199A (zh) | 2026-05-12 |
| AU2023384497A1 (en) | 2025-06-12 |
| IL320949A (en) | 2025-07-01 |
| TW202421665A (zh) | 2024-06-01 |
| KR20250110345A (ko) | 2025-07-18 |
| JP2025539145A (ja) | 2025-12-03 |
| CL2025001474A1 (es) | 2025-09-05 |
| CN122277746A (zh) | 2026-06-26 |
| US20250154279A1 (en) | 2025-05-15 |
| CN121378482A (zh) | 2026-01-23 |
| EP4623005A1 (en) | 2025-10-01 |
| CN120225562A (zh) | 2025-06-27 |
| MX2025005847A (es) | 2025-06-02 |
| CN122255279A (zh) | 2026-06-23 |
| CO2025006994A2 (es) | 2025-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021527431A5 (es) | ||
| IL278574B2 (en) | Glycan-interacting compounds and methods of use | |
| CN111246882A (zh) | 抗il1rap抗体 | |
| AR111630A1 (es) | ANTICUERPOS ANTI-SIRPa | |
| JP2022526764A5 (es) | ||
| RU2014138038A (ru) | Фармацевтическая композиция для лечения профилактики рака | |
| RU2014138040A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| RU2014138039A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| AU2018346447A1 (en) | Restoration of T cell activity via the CD39/CD73 axis | |
| JP2022533538A5 (es) | ||
| JP2017186337A5 (es) | ||
| JP2024531409A5 (es) | ||
| RU2014138041A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| JP2013543498A5 (es) | ||
| RU2017114968A (ru) | Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171) | |
| JP2017521054A5 (es) | ||
| RU2018123709A (ru) | Новые антитела для лечения онкологических заболеваний | |
| JP2023518153A5 (es) | ||
| RU2016141285A (ru) | Биспецифические антигенсвязывающие полипептиды | |
| AR127271A1 (es) | Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos | |
| WO2024194490A1 (en) | Combination of antibodies, or antigen-binding fragments thereof, for the treatment of cancer and composition thereof | |
| PE20251275A1 (es) | Agentes aglutinantes 5t4 y usos de los mismos | |
| AR132159A1 (es) | Anticuerpos anti-b7h3 y métodos de uso | |
| RU2020128108A (ru) | Антитело против cd25 для опухоль-специфической клеточной деплеции | |
| AR130865A1 (es) | Agentes de unión de msln y cd3 y métodos de uso de estos |